Human Microbiome Market

The report "Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030", is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.

Browse 250 market data Tables and 50 Figures spread through 300 Pages and in-depth TOC on "Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

Emergence of postbiotics is set to serve as potential opportunity for human microbiome market expansion. Postbiotics, which comprise metabolites and cell components that are generated by probiotics, have the potential to provide health benefits and applications are influencing human the human microbiome market. Their advancement broadens the scope of microbiome-based therapeutics and products, resulting in the increase in research, investment, and commercialization within the microbiome sector. The future landscape of microbiome interventions and treatments is being influenced by this trend. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023.

The human microbiome market study covers probiotics, prebiotics, and synbiotics. Probiotics accounted for the largest share in the human microbiome market in 2023.

An expanding segment in human microbiome therapeutics, probiotics are necessary to restore therefore preserving gut health by means of focused microbial treatments. Driven by growing consumer knowledge of the advantages of probiotics for gut health, immunity, and general wellness, the probiotics market has attracted major interest recently. For Instance, using antibiotics frequently results in severe dysbiosis by indiscriminately impacting both dangerous and helpful gut microorganisms.

Apart from probiotics, over the projection period, synbiotics are expected to have the highest CAGR. Combining prebiotics and probiotics, synbiotics improve gut health and balance the flora. Their evolution results in innovative product concepts and therapeutic alternatives, therefore stimulating more research, investment, and product launches. Emerging SMEs and startups are looking at the synbiotics niche capitalizing on the growing market trend. Companies like Seed Health, Inc. (US) concentrate on developing synbiotics for different diseases as dietary supplements.

The gastrointestinal diseases segment accounted for the largest share by disease segment in the human microbiome market in 2023.

By Disease, infectious diseases, gastrointestinal diseases, endocrine and metabolic disorders, and other diseases constitute the Human Microbiome market. The segment of gastrointestinal diseases held the biggest share in the human microbiome market in 2023. Gastrointestinal diseases include celiac disease, irritable bowel syndrome (IBS), lactose intolerance, chronic diarrhea, constipation, gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), among others. Several clinical trials are investigating the effect of human microbiome drugs and microbiome-based probiotics to alleviate the effects of gastrointestinal diseases such as NCT04970446 which investigates the effect of BIOMICTRA an approved FMT product in ulcerative colitis. The gastrointestinal disease segment within the human microbiome market is propelled by increasing demand for personalized therapies and supported by regulatory approvals and a large clinical pipeline and also validated by a robust pipeline of drugs investigating their role in treating these diseases.

The live biotherapeutic products segment accounted for the largest share by type segment in the human microbiome market in 2023.

By Type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live biotherapeutic products, and others segment the human microbiome market. BCT/ FMT accounted for the second largest market share driven by approved products in this segment by several prominent players in the human microbiome space. The segment with the second largest proportion of the human microbiome market in 2023 is the Live biotherapeutic products segment (LBPs). LBPs represent a novel class of medication derived from the human gut microbiome. These products contain live organisms, such as bacteria, and are intended for the prevention, treatment, or cure of diseases in humans.

Unlike vaccines, LBPs are generally not administered by injection. The increasing use of antibiotics, resulting in dysbiosis and antibiotic-resistant pathogens, further drives the market for LBPs. Additionally, the demand for personalized treatment solutions propels the development of LBPs designed to restore eubiosis and offer targeted therapies.

The hospitals and clinics segment accounted for the largest share by end user segment in the human microbiome market in 2023.

The human microbiome market is segmented by end users, hospitals and clinics, long-term care facilities, and other end users segment. The segment with the biggest share in the human microbiome market in 2023 was Hospitals and clinics. Hospitals are environments with strict clinical guidelines,  legal mandates, and standards which guarantee that these therapies are carried out in a sterile, under control environment. To successfully execute operations like EMT and BCT, monitor patient outcomes, and control any possible consequences, hospitals have the required infrastructure—that is, specialized facilities and qualified medical experts. Hospitals also include Advanced diagnostic techniques and laboratory capacity which provides improved access and diagnosis for rapid treatment through microbiome based therapies. This improves the safety and efficacy of the treatments, therefore, hospitals are essential for their implementation in clinical practice.

The North American region accounted for the largest share of the Human Microbiome market in 2023.

The Human Microbiome market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest regional market for Human Microbiomes in 2023, while Europe is the second-largest market. US was the major shareholder of revenue in this region along with highest CAGR. The development of US as a prominent player in this region can be attributed to availability of infrastructure for human microbiome product development, regulatory approval for niche products such as FMT, presence of prominent players in the human microbiome space along with the large investments across human microbiome market by organizations and the government. APAC was the fastest growing region in the human microbiome market. China was major contributor to the revenue of this region, mainly as a result of human microbiome market in china which is driven by investments across R&D, Emerging microbiome start-ups and SMEs, and aging population which demands for more advanced and personalized therapies. While, in the European human microbiome market UK and Germany majorly contribute to the revenue.

Key players in the Human Microbiome market are Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US).

Don’t miss out on business opportunities in Human Microbiome Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]